MDL | MFCD00977636 |
---|---|
Molecular Weight | 309.18 |
Molecular Formula | C12H9BrN2OS |
SMILES | O=C(C1=CC=CC=C1/N=C/C2=CC=C(S2)Br)N |
IC50: 5 μM (IMP1 c-Myc mRNA internation) [1]
The oncofetal mRNA-binding protein, IMP1 binds to and stabilizes c-Myc, β-TrCP1, and other oncogenic mRNAs, it leads to increased expression of the proteins encoded by its target mRNAs
[1]
.
BTYNB (10 uM; 0.5-1 hour) enhances the degradation rate of c-Myc mRNA in SK-MEL2 cells
[1]
.
BTYNB (10-40 uM; 72 hours) degrades c-Myc expression in a dose-dependent manner in SK-MEL2 cells
[1]
.
BTYNB (10-40 uM; 72 hours) decreases IMP1 expression in a dose-dependent manner in SK-MEL2 cells
[1]
.
BTYNB (1-40 μM; 72 hours) decreases levels of CDC34, CALM1, β-TRCP1, and Col5A1 mRNAs expression in T47D/(A1-2) cells in the presence of hormone
[1]
.
BTYNB elicits a robust dose-dependent inhibition of cell proliferation in IMP1-positive cells with IC
50
of 2.3 μM, 3.6 μM, and 4.5 μM in ES-2, IGROV-1, and SK-MEL2 cells, respectively. BTYNB has no effects on IMP1-negative cells and demonstrates no inhibition of cell proliferation at all concentrations tested, including 50 μM
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
RT-PCR [1]
Cell Line: | T47D/(A1-2) cells |
Concentration: | 1 μM; 10 μM; 20 μM; 30 μM; 40 μM |
Incubation Time: | |
Result: | Reduced the levels of a diverse set of cancer-related IMP1 mRNA targets. |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
DMSO : 62.5 mg/mL ( 202.15 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.2344 mL | 16.1718 mL | 32.3436 mL |
5 mM | 0.6469 mL | 3.2344 mL | 6.4687 mL |
10 mM | 0.3234 mL | 1.6172 mL | 3.2344 mL |